#1 Clinical Trials Search in Europe

Immunoglobulin M

This article explores the use of Immunoglobulin M (IgM) in clinical trials, focusing on its potential benefits for patients with sepsis and peritonitis. Two ongoing studies are investigating the effectiveness of IgM-enriched immunoglobulin therapy in treating these serious conditions. These trials aim to improve patient outcomes by personalizing dosages and comparing different treatment approaches.

Table of Contents

What is Immunoglobulin M (IgM)?

Immunoglobulin M, or IgM, is a type of antibody that plays a crucial role in our body’s immune response. It is one of the first antibodies produced by our immune system when it encounters harmful substances like bacteria or viruses. IgM-enriched immunoglobulin therapy is a treatment that contains high levels of IgM, along with other types of immunoglobulins such as IgA and IgG.[1]

Medical Conditions Treated with IgM-Enriched Immunoglobulin

IgM-enriched immunoglobulin therapy is being studied for its potential to treat severe infections, particularly:

  • Sepsis: A life-threatening condition that occurs when the body’s response to infection causes widespread inflammation and organ failure.[1]
  • Septic shock: A severe form of sepsis that causes a dangerous drop in blood pressure.[2]
  • Peritonitis: An inflammation of the lining of the abdominal cavity, often caused by infection.[1]

How IgM-Enriched Immunoglobulin Works

IgM-enriched immunoglobulin therapy works by boosting the body’s immune response to severe infections. It provides additional antibodies that can help fight off harmful bacteria and viruses. This treatment is particularly useful when a patient’s own immune system is overwhelmed or not functioning properly due to severe infection.[1]

How the Treatment is Administered

IgM-enriched immunoglobulin is given as an intravenous infusion, which means it’s delivered directly into the bloodstream through a vein. The dosage and duration of treatment can vary depending on the specific condition being treated and the patient’s individual needs. In some cases, the dose may be personalized based on the patient’s IgM levels in their blood.[1][2]

Current Clinical Trials

There are ongoing clinical trials to evaluate the effectiveness and safety of IgM-enriched immunoglobulin therapy:

  • A study is investigating its use in patients with peritonitis and sepsis after infection control.[1]
  • Another trial is comparing personalized dosing based on serum IgM levels to standard dosing in patients with septic shock.[2]

These studies aim to determine if IgM-enriched immunoglobulin therapy can improve outcomes such as reducing organ failure, decreasing mortality rates, and shortening hospital stays for patients with severe infections.[1][2]

Potential Benefits

If proven effective, IgM-enriched immunoglobulin therapy could offer several benefits for patients with severe infections:

  • Reduced risk of death from sepsis and septic shock[1][2]
  • Improved organ function and reduced risk of organ failure[1]
  • Shorter stays in the intensive care unit (ICU) and hospital[2]
  • Fewer days on mechanical ventilation and other life-support measures[2]

Possible Side Effects and Precautions

While IgM-enriched immunoglobulin therapy shows promise, it’s important to be aware of potential side effects and precautions:

  • Allergic reactions: Some people may be allergic to the components of the immunoglobulin preparation.[2]
  • Kidney function: Patients with severe kidney problems may need special consideration before receiving this treatment.[1][2]
  • Pregnancy and breastfeeding: The safety of this treatment during pregnancy or while breastfeeding is not yet established.[1][2]

It’s crucial to discuss any concerns or questions about IgM-enriched immunoglobulin therapy with your healthcare provider. They can provide personalized advice based on your specific medical condition and needs.

Aspect Trial 1 Trial 2
Main Focus Peritonitis and sepsis Septic shock
Primary Objective Change in Multiple Organ Failure (MOF) score Reduction in 28-day mortality
Treatment Pentaglobin® (IgM-enriched immunoglobulin) Personalized IgM-enriched immunoglobulin dosing
Key Inclusion Criteria Secondary or quaternary peritonitis, SOFA score ≥ 8, IL-6 ≥ 1000 pg/ml Septic shock < 24 hours, IgM-titers < 60mg/dl
Key Exclusion Criteria Life expectancy < 90 days, chronic renal dysfunction requiring dialysis Shock of uncertain diagnosis, hypersensitivity to IgM preparation
Duration of Treatment Up to 5 days Up to 7 days
Follow-up Period 90 days 90 days

FAQ

  • What is Immunoglobulin M (IgM) and how is it being used in these clinical trials? Immunoglobulin M (IgM) is an antibody that plays a crucial role in the immune system's response to infections. In these clinical trials, IgM is being used as part of an enriched immunoglobulin therapy to treat patients with sepsis, septic shock, and peritonitis. The therapy aims to boost the patient's immune response and improve their ability to fight off severe infections.
  • What are the main objectives of these clinical trials? The main objectives of these trials are to evaluate the effectiveness and safety of IgM-enriched immunoglobulin therapy in reducing mortality rates and improving organ function in patients with sepsis, septic shock, and peritonitis. One trial is specifically comparing personalized dosing based on serum IgM levels to standard dosing, while the other is focusing on changes in multiple organ failure scores.
  • Who is eligible to participate in these clinical trials? Eligibility criteria vary between the trials, but generally include adult patients (over 18 years old) with diagnosed sepsis, septic shock, or peritonitis. Specific requirements include certain severity scores (like SOFA score ≥ 8), IL-6 levels, and timing of antibiotic therapy. Patients with certain pre-existing conditions, such as chronic kidney dysfunction requiring dialysis or pregnancy, are typically excluded.
  • What are the potential benefits of participating in these trials? Participants may benefit from receiving advanced immunoglobulin therapy that could potentially improve their chances of survival and reduce the severity of organ dysfunction. Additionally, they contribute to important medical research that may help future patients with similar conditions. However, it's important to note that as with any clinical trial, there are no guarantees of personal benefit.
  • Are there any risks associated with participating in these IgM clinical trials? While the trials are designed to be as safe as possible, there are always potential risks associated with any medical treatment. Possible risks include allergic reactions to the immunoglobulin therapy and other adverse events. The trials closely monitor participants for any side effects or complications. It's important for potential participants to discuss all possible risks and benefits with their healthcare providers before deciding to join a trial.

Ongoing Clinical Trials on Immunoglobulin M

  • Study on the Effectiveness and Safety of IgM-Enriched Immunoglobulin Therapy for Patients with Septic Shock

    Recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    Italy

  • Study on the Effects of Immunoglobulin A, G, and M in Patients with Peritonitis and Sepsis After Infection Control

    Recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    Austria Germany

  • Study on Pentaglobin for Treating Fever in Acute Leukemia or Stem Cell Transplant Patients with Resistant Bacteria

    Not recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    Italy

Glossary

  • Immunoglobulin M (IgM): A type of antibody produced by B cells that plays a crucial role in the early stages of the immune response to infections.
  • Sepsis: A life-threatening condition that occurs when the body's response to infection causes widespread inflammation and organ dysfunction.
  • Septic shock: A severe form of sepsis characterized by a significant drop in blood pressure and organ failure, often requiring vasopressors to maintain adequate blood pressure.
  • Peritonitis: Inflammation of the peritoneum, the tissue lining the inner wall of the abdomen and covering the abdominal organs.
  • Multiple Organ Failure (MOF) score: A scoring system used to assess the degree of organ dysfunction in critically ill patients, typically evaluating the function of organs such as the lungs, heart, kidneys, liver, and blood.
  • SOFA score: Sequential Organ Failure Assessment score, a system used to track a patient's status during their stay in an intensive care unit (ICU) to determine the extent of organ function or failure.
  • Vasopressor: A type of medication used to raise blood pressure in patients with severely low blood pressure, often used in treating septic shock.
  • Interleukin-6 (IL-6): A protein involved in the immune response and inflammation, often used as a marker of infection severity in sepsis.
  • ICU-acquired weakness: A condition of muscle weakness that develops during a patient's stay in the intensive care unit, often assessed using the Medical Research Council (MRC) Scale.
  • Ventilation-free days (VFDs): A measure used in clinical trials to assess how long a patient can breathe without mechanical ventilation support.

References

  1. http://clinicaltrials.eu/trial/study-on-the-effects-of-immunoglobulin-a-g-and-m-in-patients-with-peritonitis-and-sepsis-after-infection-control/
  2. http://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-igm-enriched-immunoglobulin-therapy-for-patients-with-septic-shock/